Evidence map›Paper›PMID 36065728›Full record

ArticleThe Journal of antimicrobial chemotherapy2022

Country data on AMR in Mexico in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.

Didem Torumkuney, Carlos de la Torre, Karen Langfeld, Norma Patricia Lopez-Turrent, Cristiana Ossaille Beltrame

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Intestinal and Extraintestinal Pathotypes ofAntibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Didem TorumkuneyGlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Carlos de la TorreDepartment of Paediatric Otolaryngology, Hospital Infantil de México, Federico Gómez, Mexico City, Mexico.
Karen LangfeldGlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Norma Patricia Lopez-TurrentGlaxoSmithKline, Torre Mítikah Piso 19 y 20. Circuito Interior Avenida Río Churubusco 601, Col. Xoco, Benito Juárez, C.P. 03330 Mexico City, Mexico.
Cristiana Ossaille BeltrameGlaxoSmithKline, Estrada dos Bandeirantes, 8464, Jacarepaguá, 22783-110 Rio de Janeiro, Brazil.
GlaxoSmithKline (United Kingdom) · GBGlaxoSmithKline (Brazil) · BRHospital Infantil de México Federico Gómez · MX

Funding

GlaxoSmithKline
6 · The paper itself

Abstract

backgroundAntimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action.

objectivesTo review AMR in Mexico and initiatives addressing it. Identifying any areas where more information is required will provide a call to action to minimize any further rises in AMR and to improve patient outcomes.

methodsNational AMR initiatives in Mexico, antibiotic use and prescribing, and availability of susceptibility data, particularly the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines commonly used in Mexico for specific CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) were also reviewed, along with local antibiotic availability. Insights from a local clinician were sought to contextualize this information.

conclusionsThe Mexican national AMR strategy was published in 2018. This comprised similar objectives to the Global Action Plan from the World Health Assembly (2015) and was compulsory, requiring full compliance from members of the National Health System. Historically, antibiotic consumption in Mexico has been high, however, between 2000 and 2015, consumption fell, in sharp contrast to the majority of countries. Mexico lacks a national surveillance network for AMR, however there are several ongoing global surveillance studies providing local antibiotic susceptibility data. International and local antibiotic prescribing guidelines for CA-RTIs are used. A more standardized inclusive approach in developing local guidelines, using up-to-date local surveillance data of isolates from community-acquired infections, could make guideline use more locally relevant. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development in Mexico and improve patient outcomes.

Indexed as

Community-Acquired InfectionsCOVID-19PneumoniaRespiratory Tract InfectionsAcute DiseaseAnti-Bacterial AgentsHealth Services AccessibilityHumansMexicoAnti-Bacterial Agents

Identifiers

PMID36065728
PMCPMC9445859
OpenAlexW4294724938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.